{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=intramuscularly+%28IM+injection%29&page=8",
    "query": {
      "intervention": "intramuscularly (IM injection)",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 204,
    "total_pages": 21,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=intramuscularly+%28IM+injection%29&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=intramuscularly+%28IM+injection%29&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T14:30:50.667Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05348993",
      "title": "Single or Repeat Dose of G03-52-01 in Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy",
        "Botulinum Toxin"
      ],
      "interventions": [
        {
          "name": "G03-52-01",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 622,
      "start_date": "2022-06-15",
      "completion_date": "2025-02-18",
      "has_results": true,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-10-14T14:30:50.667Z",
      "location_count": 15,
      "location_summary": "Mobile, Alabama • Tempe, Arizona • Fort Myers, Florida + 11 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "El Dorado",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05348993"
    },
    {
      "nct_id": "NCT04176133",
      "title": "Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Entolimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Influenza vaccine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Robert J. Pignolo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2019-10-30",
      "completion_date": "2022-03-30",
      "has_results": true,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-10-14T14:30:50.667Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04176133"
    },
    {
      "nct_id": "NCT00128219",
      "title": "Prevention of GBS Colonization Via Immunity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Beta Haemolytic Streptococcal Infection"
      ],
      "interventions": [
        {
          "name": "GBS III-TT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tetanus and diptheria toxoids vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 667,
      "start_date": "2003-07",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2015-01-27",
      "last_synced_at": "2026-10-14T14:30:50.667Z",
      "location_count": 3,
      "location_summary": "Augusta, Georgia • Pittsburgh, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00128219"
    },
    {
      "nct_id": "NCT00980005",
      "title": "Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "GSK investigational vaccine GSK1557482A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Years to 17 Years"
      },
      "enrollment_count": 2116,
      "start_date": "2009-10-13",
      "completion_date": "2010-06-17",
      "has_results": true,
      "last_update_posted_date": "2018-09-21",
      "last_synced_at": "2026-10-14T14:30:50.667Z",
      "location_count": 28,
      "location_summary": "Birmingham, Alabama • Benton, Arkansas • Huntington Beach, California + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Benton",
          "state": "Arkansas"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Paramount",
          "state": "California"
        },
        {
          "city": "West Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00980005"
    },
    {
      "nct_id": "NCT02264288",
      "title": "Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peripheral Arterial Disease",
        "Diabetic Foot"
      ],
      "interventions": [
        {
          "name": "PDA-002",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Celularity Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 159,
      "start_date": "2014-10-23",
      "completion_date": "2018-02-27",
      "has_results": true,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-10-14T14:30:50.667Z",
      "location_count": 45,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02264288"
    },
    {
      "nct_id": "NCT04111172",
      "title": "A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma",
        "Colorectal Adenocarcinoma",
        "Gastric Adenocarcinoma",
        "Clinical Stage II Gastric Cancer AJCC v8",
        "Clinical Stage IIA Gastric Cancer AJCC v8",
        "Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage IIB Gastric Cancer AJCC v8",
        "Clinical Stage III Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage III Gastric Cancer AJCC v8",
        "Malignant Solid Neoplasm",
        "Pathologic Stage II Gastric Cancer AJCC v8",
        "Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIB Gastric Cancer AJCC v8",
        "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage III Gastric Cancer AJCC v8",
        "Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIIA Gastric Cancer AJCC v8",
        "Pathologic Stage IIIB Gastric Cancer AJCC v8",
        "Pathologic Stage IIIC Gastric Cancer AJCC v8",
        "Stage I Pancreatic Cancer AJCC v8",
        "Stage IA Pancreatic Cancer AJCC v8",
        "Stage IB Pancreatic Cancer AJCC v8",
        "Stage II Pancreatic Cancer AJCC v8",
        "Stage IIA Pancreatic Cancer AJCC v8",
        "Stage IIB Pancreatic Cancer AJCC v8",
        "Stage III Colorectal Cancer AJCC v8",
        "Stage III Pancreatic Cancer AJCC v8",
        "Stage IIIA Colorectal Cancer AJCC v8",
        "Stage IIIB Colorectal Cancer AJCC v8",
        "Stage IIIC Colorectal Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IVA Colorectal Cancer AJCC v8",
        "Stage IVB Colorectal Cancer AJCC v8",
        "Malignant Digestive System Neoplasm",
        "Small Intestinal Adenocarcinoma",
        "Stage III Small Intestinal Adenocarcinoma AJCC v8",
        "Stage IIIA Small Intestinal Adenocarcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2020-11-10",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-14T14:30:50.667Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04111172"
    },
    {
      "nct_id": "NCT06919796",
      "title": "mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers",
        "SARS CoV-2"
      ],
      "interventions": [
        {
          "name": "COMIRNATY®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "PharmaJet, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 40,
      "start_date": "2025-05-01",
      "completion_date": "2026-11-25",
      "has_results": false,
      "last_update_posted_date": "2025-04-15",
      "last_synced_at": "2026-10-14T14:30:50.667Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06919796"
    },
    {
      "nct_id": "NCT00423046",
      "title": "Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infections, Papillomavirus",
        "Papillomavirus Vaccines"
      ],
      "interventions": [
        {
          "name": "GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gardasil ® (Merck & Co. Inc)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 1106,
      "start_date": "2007-01-24",
      "completion_date": "2012-05-14",
      "has_results": true,
      "last_update_posted_date": "2020-01-02",
      "last_synced_at": "2026-10-14T14:30:50.667Z",
      "location_count": 40,
      "location_summary": "Chandler, Arizona • San Diego, California • San Francisco, California + 36 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Vista",
          "state": "California"
        },
        {
          "city": "West Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00423046"
    },
    {
      "nct_id": "NCT06855160",
      "title": "A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chickenpox"
      ],
      "interventions": [
        {
          "name": "Candidate varicella vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Marketed varicella vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MMR vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis A vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PCV (pneumococcal conjugate vaccine) 13",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PCV 20",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vaxneuvance",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "15 Months",
        "sex": "ALL",
        "summary": "12 Months to 15 Months"
      },
      "enrollment_count": 911,
      "start_date": "2025-04-17",
      "completion_date": "2027-02-02",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-10-14T14:30:50.667Z",
      "location_count": 13,
      "location_summary": "Tucson, Arizona • Huntington Park, California • Sherman Oaks, California + 10 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06855160"
    },
    {
      "nct_id": "NCT04397003",
      "title": "Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Extensive-stage Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Neoantigen DNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "TDS-IM v2.0 Device",
          "type": "DEVICE"
        },
        {
          "name": "Peripheral blood draws",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2022-03-30",
      "completion_date": "2029-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-10-22",
      "last_synced_at": "2026-10-14T14:30:50.667Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04397003"
    }
  ]
}